Human papillomavirus vaccine introduction in low and middle income countries: guidance on the use of cost-effectiveness models Mark Jit1, Nadia Demarteau2†, Elamin Elbasha3†, Gary Ginsberg4†, Jane Kim5†, Naiyana Praditsitthikorn6†, Edina Sinanovic7† and Raymond Hutubessy8* † Contributed equally 8

Adapting a dynamic transmission model developed by National University of Singapore to the Philippines context, in order to address policy questions around COVID-19 vaccine choice, target population for booster doses, and the impact of social gatherings on COVID-19 spread.

To calibrate the Covid M SEIR model to Thailand and to build capacity to use the model to address policy questions in Thailand. This project will address COVID-19 vaccination policy questions, such as frequency and target population for booster doses, as well as development of web-based applications to communicate the results to policymakers and ot

(Reuters Health) – A study of nearly 190,000 young women injected with Merck & Co’s human papillomavirus vaccine Gardasil found no new safety concerns.Researchers said the only side effects they observed – rare cases of skin infections and fainting – were benign and expected.“This analysis was v

To support government decision-making to address the COVID-19 outbreak, the National Data Management Center (NDMC) of the Ethiopia Public Health Institute (EPHI) conducted a systematic review of the economic evaluations of public health measures for the prevention and control of pandemics. The study

Abstract Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of natio

Vaccines have been a game-changer in the fight against COVID-19. Yet, vaccine hesitancy has impeded its uptake, impacting public health efforts. At the outset of the pandemic, people had doubts about this unfamiliar virus and subsequently, the vaccine: misinformation, rumours, and doubts about COVID

This is the third visit of the HITAP team to the Philippines and last activity of the two vaccine evaluations project collaboration between NCPAM and HITAP with the support of Rockefeller Foundation through NICE International. The project started in March 2013 and ended in March 2014. With extensive

HITAP emphasise the lead role of Thailand in public health system as the host of the Health Technology Assessment (HTA) conference at the regional level gathering around 300 academics from 20 countries to present their research work, build a network for health policy recommendations development, and

Bhutan\'s Ministry of Health, especially the Essential Medicine and Technology Division (EMTD), is one of HITAP\'s long-term partners. From 2018 to 2019, HITAP with PATH supported Bhutan to conduct an economic evaluation for the implementation of a national program for rotavirus vaccination. HITAP also provided and continues to find opportunities f